Abstract:Hepatocyte growth factor (HGF) is a pleiotropic cytokine composed of an α-chain and a β-chain, and these chains contain four kringle domains and a serine protease-like structure, respectively. The receptor for HGF was identified as the c-met proto-oncogene product of transmembrane receptor tyrosine kinase. HGF-induced signaling through the receptor Met provokes dynamic biological responses that support morphogenesis, regeneration, and the survival of various cells and tissues, which includes hepatocytes, renal tubular cells, and neurons. Characterization of tissue-specific Met knockout mice has further indicated that the HGF-Met system modulates immune cell functions and also plays an inhibitory role in the progression of chronic inflammation and fibrosis. However, the biological actions that are driven by the HGF-Met pathway all play a role in the acquisition of the malignant characteristics in tumor cells, such as invasion, metastasis, and drug resistance in the tumor microenvironment. Even though oncogenic Met signaling remains the major research focus, the HGF-Met axis has also been implicated in infectious diseases. Many pathogens try to utilize host HGF-Met system to establish comfortable environment for infection. Their strategies are not only simply change the expression level of HGF or Met, but also actively hijack HGF-Met system and deregulating Met signaling using their pathogenic factors. Consequently, the monitoring of HGF and Met expression, along with real-time detection of Met activation, can be a beneficial biomarker of these infectious diseases. Preclinical studies designed to address the therapeutic significance of HGF have been performed on injury/disease models, including acute tissue injury, chronic fibrosis, and cardiovascular and neurodegenerative diseases. Likewise, manipulating the HGF-Met system with complete control will lead to a tailor made treatment for those infectious diseases.

Progress in researches of hepatocyte growth factor and its receptor for new drug development

HGF/c-Met Axis: the Advanced Development in Digestive System Cancer

Research Progress in the Mechanism of Molecular Targeted Anti-tumor Drugs

Research Progress of MicoRNA in Molecular Targeting Treatment of Hepatocellular Carcinoma

HGF/c-Met: A Key Promoter in Liver Regeneration

Clinical development of dual tyrosine kinase inhibitors targeting vascular endothelial growth factor receptor and platelet- derived growth factor receptor

The Progress of Antibody-Based Anti-Tumor Drugs Targeting HGF/c-Met Signaling Pathway

[Research Progress of HGF/c-MET Inhibitor in the Treatment of Non-small Cell Lung Cancer].

Progress of Research on HGF/SF

Research Progress on Biological Functions of Hepatocyte Growth Factor During Muscle Development

Hepatocyte growth factor in physiology and infectious diseases

Vascular Endothelial Growth Factors and Liver Diseases.

[Advances in Mesenchymal to Epithelial Transition Factor Signaling Pathway and Inhibitors].

[Research Progress in Hepatocyte Growth Factor/Mesenchymal-epithelial Transition Factor Signaling Pathway:Effects and Mechanisms on Resistance to Targeted Therapy for Non-small Cell Lung Cancer].

Targeting Hepatocyte Growth Factor/c‐mesenchymal–epithelial Transition Factor Axis in Hepatocellular Carcinoma: Rationale and Therapeutic Strategies

Progress in Effects of the HGF/SF-c-Met on Progression of Tumors and Inhibitors of Its Pathway

Research Progress of C-Met Signaling Pathway and Antagonists

Progress and Challenge in Development of Biotherapeutics Targeting MET Receptor for Treatment of Advanced Cancer.

Advances of Fibroblast Growth Factor/Receptor Signaling Pathway in Hepatocellular Carcinoma and its Pharmacotherapeutic Targets

Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement

Research progress on the development of hepatocyte growth factor/c-Met signaling pathway in gastric cancer: A review